Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Monday, November 9 2009 4:36pm ET - U.S. Markets Closed.
Industry Center - Diagnostic Substances
Industry Center > Diagnostic Substances > Immunomedics, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Immunomedics, Inc. Company Profile
Immunomedics is focused on developing humanized monoclonal antibodies (MAbs) to treat cancer and other serious diseases. Its lead product, epratuzumab, is in late-stage development for the treatment of lupus; biopharmaceutical firm UCB has licensed the drug for further applications in autoimmune diseases. Immunomedics is also conducting clinical trials for epratuzumab as an oncology treatment for non-Hodgkin's lymphoma and leukemia. The company has other drugs in clinical trials to treat various cancers, including veltuzumab (lymphoma) and milatuzumab (multiple myeloma). It also makes diagnostic imaging products; subsidiary IBC Pharmaceuticals develops radiotherapeutics for applications in oncology treatments.
Headlines for Immunomedics, Inc.
New Star Analyst Rankings for Immunomedics, Inc.
StarMine - Mon 9:24 am ET
IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online - Fri Nov 6
Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
GlobeNewswire - Fri Nov 6
Immunomedics to Present at Upcoming Conferences
GlobeNewswire - Tue Oct 27
More Headlines...
More on Immunomedics, Inc.
Quote SEC
Chart Msgs
News Insider
Profile Financials
Reports Analyst Ratings
Research    
Contact Information
Address: 300 American Rd.
Morris Plains, NJ 07950
Phone:973-605-8200
Fax:973-605-8282
Financial Highlights
Fiscal Year End:June
Revenue (2009):30.00 M
Revenue Growth (1 yr):722.30%
Employees (2009):120
Employee Growth (1 yr):2.60%
Key People
Chairman, Chief Strategic Officer, Chief Sceintific Officer,: David M. Goldenberg
President, CEO, and Director: Cynthia L. Sullivan
SVP Finance and Business Development, and CFO: Gerard G. (Gerry) Gorman
Industry Information
Sector: Healthcare
Industry: Diagnostic Substances
Top Competitors
Biogen Idec Inc. (biib)
Genentech, Inc.
GlaxoSmithKline plc (gsk)
 


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2009 Morningstar, Inc. All Rights Reserved. Company information © 2009 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2009, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo! nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo! site, a user agrees not to redistribute the information found therein.

Questions or Comments?